Details for Patent: 8,791,122
✉ Email this page to a colleague
Which drugs does patent 8,791,122 protect, and when does it expire?
Patent 8,791,122 protects UPTRAVI and is included in two NDAs.
This patent has fifty-nine patent family members in thirty-three countries.
Summary for Patent: 8,791,122
| Title: | Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide and method for producing the same |
| Abstract: | A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide (hereinafter referred to as "compound A"). A Form-I crystal of compound A shows diffraction peaks at 9.4 degrees, 9.8 degrees, 17.2 degrees and 19.4 degrees in the powder X-ray diffraction spectrum thereof. A Form-II crystal of compound A shows diffraction peaks at 9.0 degrees, 12.9 degrees, 20.7 degrees and 22.6 degrees in the powder X-ray diffraction spectrum thereof. A Form-III crystal of compound A shows diffraction peaks at 9.3 degrees, 9.7 degrees, 16.8 degrees, 20.6 degrees and 23.5 degrees in the powder X-ray diffraction spectrum thereof. |
| Inventor(s): | Itou; Hideyuki (Kyoto, JP) |
| Assignee: | Nippon Shinyaku Co., Ltd. (Kyoto, JP) |
| Application Number: | 13/379,531 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,791,122 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; Formulation; |
Drugs Protected by US Patent 8,791,122
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actelion | UPTRAVI | selexipag | POWDER;INTRAVENOUS | 214275-001 | Jul 29, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-001 | Dec 21, 2015 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-002 | Dec 21, 2015 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-003 | Dec 21, 2015 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-004 | Dec 21, 2015 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,791,122
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2009-151727 | Jun 26, 2009 |
| Japan | 2009-151728 | Jun 26, 2009 |
| Japan | 2009-151729 | Jun 26, 2009 |
| PCT Information | |||
| PCT Filed | June 25, 2010 | PCT Application Number: | PCT/JP2010/060798 |
| PCT Publication Date: | December 29, 2010 | PCT Publication Number: | WO2010/150865 |
International Family Members for US Patent 8,791,122
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2447254 | ⤷ Sign Up | PA2018008 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2447254 | ⤷ Sign Up | C20180012 00263 | Estonia | ⤷ Sign Up |
| European Patent Office | 2447254 | ⤷ Sign Up | 2018015 | Norway | ⤷ Sign Up |
| European Patent Office | 2447254 | ⤷ Sign Up | 325 10-2018 | Slovakia | ⤷ Sign Up |
| European Patent Office | 2447254 | ⤷ Sign Up | PA2018008,C2447254 | Lithuania | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
